Search
Results: 21
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK
Robert Hawkins, Kate Fife, Michael Hurst, Meng Wang, Niroshini Naicker, Sarah Nolasco, Tim Eisen, Athena Matakidou, Jason Gordon
Jul 28, 2021
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro.
Rafia S Al-Lamki, Nicholas J Hudson, John R Bradley, Anne Y Warren, Tim Eisen, Sarah J Welsh, Antony CP Riddick, Fiach C O'Mahony, Arran Turnbull, Thomas Powles, Scotrrcc Collaborative, Antonio Reverter, David J Harrison, Grant D Stewart
Apr 03, 2020
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we...
Irreversible electroporation in renal tumours
We review the safety and early oncological outcomes of irreversible electroporation (IRE), a novel non-thermal ablation technique, in small renal masses (SRMs). Following PROSPERO registration (CRD42020197943), a systematic...
Genomics and clinical correlates of renal cell carcinoma.
PURPOSE: Clear cell, papillary cell, and chromophobe renal cell carcinomas (RCCs) have now been well characterised thanks to large collaborative projects such as The Cancer Genome Atlas (TCGA). Not only has knowledge of the...
evolution Genomics mutations Prognosis renal cancer Therapy Carcinoma Renal Cell DNA-Binding Proteins Genomics Histone-Lysine N-Methyltransferase Humans Kidney Neoplasms Mutation Nuclear Proteins PTEN Phosphohydrolase Telomerase Transcription Factors Tumor Suppressor Protein p53 Tumor Suppressor Proteins Ubiquitin Thiolesterase Von Hippel-Lindau Tumor Suppressor Protein
The MITRE trial protocol
Nicola A Thompson, Grant D Stewart, Sarah J Welsh, Gary J Doherty, Matthew J Robinson, B Anne Neville, Kevin Vervier, Simon R Harris, David J Adams, Katy Dalchau, David Bruce, Nikolaos Demiris, Trevor D Lawley, Pippa G Corrie
Feb 25, 2022
BACKGROUND: The gut microbiome is implicated as a marker of response to immune checkpoint inhibitors (ICI) based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early studies...
biomarker EFFICACY Immune checkpoint inhibitor Immunotherapy Melanoma Microbiome Non-Small Cell Lung Cancer renal cancer toxicity Antibodies Viral Antigens Viral Carcinoma Non-Small-Cell Lung Disease Progression Feces Gastrointestinal Microbiome Humans Immune Checkpoint Inhibitors Kidney Neoplasms Lung Neoplasms Melanoma Microbial Consortia Neoplasms Progression-Free Survival Prospective Studies SARS-CoV-2 Skin Neoplasms
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.
Christopher G Smith, Tina Moser, Florent Mouliere, Johanna Field-Rayner, Matthew Eldridge, Anja L Riediger, Dineika Chandrananda, Katrin Heider, Jonathan CM Wan, Anne Y Warren, James Morris, Irena Hudecova, Wendy N Cooper, Thomas J Mitchell, Davina Gale, Andrea Ruiz-Valdepenas, Tobias Klatte, Stephan Ursprung, Evis Sala, Antony CP Riddick, Tevita F Aho, James N Armitage, Samantha Perakis, Martin Pichler, Maximilian Seles, Gabriel Wcislo, Sarah J Welsh, Athena Matakidou, Tim Eisen, Charles E Massie, Nitzan Rosenfeld, Ellen Heitzer, Grant D Stewart
Feb 14, 2020
BACKGROUND: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. METHODS: Here, a combination of untargeted and targeted sequencing...
European temporal trends in the use of lymph node dissection in patients with renal cancer
U Capitanio, GD Stewart, A Larcher, I Ouzaid, B Akdogan, M Roscigno, M Marszalek, P Dell'Oglio, M Salagierski, A Volpe, MC Mir, M Kriegmair, C Terrone, SD Brookman-May, F Montorsi, T Klatte, Kidney Cancer Working Group of the Young Academic Urologists (YAU) Working Party of the European Association of Urology (EAU)
Oct 04, 2017
BACKGROUND: The role of lymph node dissection (LND) in renal cell carcinoma (RCC) is still under debate. We aimed to assess the utilization rates of LND over time in Europe. METHODS: A multi-institutional database of 13,581 RCC...
Time trends in service provision and survival outcomes for patients with renal cancer treated by nephrectomy in England 2000-2010.
Ray CJ Hsu, Matthew Barclay, Molly A Loughran, Georgios Lyratzopoulos, Vincent J Gnanapragasam, James N Armitage
Jun 19, 2018
OBJECTIVE: To describe the temporal trends in nephrectomy practice and outcomes for English patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: Adult RCC nephrectomy patients treated between 2000 and 2010 were...
#KidneyCancer centralisation Nephrectomy postoperative outcomes renal cancer survival Aged Delivery of Health Care England Female Humans Kidney Neoplasms Male Middle Aged Nephrectomy Nephrons Organ Sparing Treatments Practice Patterns Physicians' Retrospective Studies Survival Analysis Time Factors Treatment Outcome
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK
Robert Hawkins, Kate Fife, Michael Hurst, Meng Wang, Niroshini Naicker, Sarah Nolasco, Tim Eisen, Athena Matakidou, Jason Gordon
Jul 17, 2020
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors
Christopher G. Smith, Tina Moser, Florent Mouliere, Johanna Field-Rayner, Matthew Eldridge, Anja L. Riediger, Dineika Chandrananda, Katrin Heider, Jonathan C. M. Wan, Anne Y. Warren, James Morris, Irena Hudecova, Wendy N. Cooper, Thomas J. Mitchell, Davina Gale, Andrea Ruiz-Valdepenas, Tobias Klatte, Stephan Ursprung, Evis Sala, Antony C. P. Riddick, Tevita F. Aho, James N. Armitage, Samantha Perakis, Martin Pichler, Maximilian Seles, Gabriel Wcislo, Sarah J. Welsh, Athena Matakidou, Tim Eisen, Charles E. Massie, Nitzan Rosenfeld, Ellen Heitzer, Grant D. Stewart
Feb 27, 2021
Abstract: Background: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods: Here, a combination of untargeted and targeted...
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors
Christopher G. Smith, Tina Moser, Florent Mouliere, Johanna Field-Rayner, Matthew Eldridge, Anja L. Riediger, Dineika Chandrananda, Katrin Heider, Jonathan C. M. Wan, Anne Y. Warren, James Morris, Irena Hudecova, Wendy N. Cooper, Thomas J. Mitchell, Davina Gale, Andrea Ruiz-Valdepenas, Tobias Klatte, Stephan Ursprung, Evis Sala, Antony C. P. Riddick, Tevita F. Aho, James N. Armitage, Samantha Perakis, Martin Pichler, Maximilian Seles, Gabriel Wcislo, Sarah J. Welsh, Athena Matakidou, Tim Eisen, Charles E. Massie, Nitzan Rosenfeld, Ellen Heitzer, Grant D. Stewart
Jun 06, 2020
Abstract: Background: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods: Here, a combination of untargeted and targeted...
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
Rafia S. Al-Lamki, Nicholas J. Hudson, John R. Bradley, Anne Y. Warren, Tim Eisen, Sarah J. Welsh, Antony C. P. Riddick, Fiach C. O’Mahony, Arran Turnbull, Thomas Powles, SCOTRRCC Collaborative SCOTRRCC Collaborative, Antonio Reverter, David J. Harrison, Grant D. Stewart
Apr 08, 2020
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we...
mTORC1 Upregulation Leads to Accumulation of the Oncometabolite Fumarate in a Mouse Model of Renal Cell Carcinoma.
Luca Drusian, Elisa Agnese Nigro, Valeria Mannella, Roberto Pagliarini, Monika Pema, Ana SH Costa, Fabio Benigni, Alessandro Larcher, Marco Chiaravalli, Edoardo Gaude, Francesco Montorsi, Umberto Capitanio, Giovanna Musco, Christian Frezza, Alessandra Boletta
Nov 01, 2018
Renal cell carcinomas (RCCs) are common cancers diagnosed in more than 350,000 people each year worldwide. Several pathways are de-regulated in RCCs, including mTORC1. However, how mTOR drives tumorigenesis in this context is...
TCA cycle cancer metabolism cancer signaling epithelial transformation Fumarate Hydratase Metabolic reprogramming papillary carcinoma rapamycin renal cancer renal cysts Animals Carcinoma Renal Cell Cells Cultured Female Fumarate Hydratase Fumarates Humans Kidney Neoplasms Male Mechanistic Target of Rapamycin Complex 1 Mice Mice Inbred C57BL Tuberous Sclerosis Complex 1 Protein Up-Regulation
The IDENTIFY study
Sinan Khadhouri, Kevin M Gallagher, Kenneth R MacKenzie, Taimur T Shah, Chuanyu Gao, Sacha Moore, Eleanor F Zimmermann, Eric Edison, Matthew Jefferies, Arjun Nambiar, Miles P Mannas, Taeweon Lee, Giancarlo Marra, Beatrice Lillaz, Juan Gómez Rivas, Jonathan Olivier, Mark A Assmus, Taha Uçar, Francesco Claps, Matteo Boltri, Tara Burnhope, Nkwam Nkwam, George Tanasescu, Nicholas E Boxall, Alison P Downey, Asim A Lal, Marta Antón-Juanilla, Holly Clarke, David HW Lau, Kathryn Gillams, Matthew Crockett, Matthew Nielsen, Yemisi Takwoingi, Naomi Chuchu, John O'Rourke, Graeme MacLennan, John S McGrath, Veeru Kasivisvanathan, IDENTIFY Study group
Sep 08, 2021
The MITRE trial protocol
Nicola A Thompson, Grant Stewart, Sarah Welsh, Gary Doherty, Matthew J Robinson, B Anne Neville, Kevin Vervier, Simon R Harris, David J Adams, Katy Dalchau, David Bruce, Nikolaos Demiris, Trevor D Lawley, Pippa G Corrie
Jan 28, 2022
BACKGROUND: The gut microbiome is implicated as a marker of response to immune checkpoint inhibitors (ICI) based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early studies...
Prognostic factors and prognostic models for renal cell carcinoma
Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
U Capitanio, GD Stewart, T Klatte, B Akdogan, M Roscigno, M Marszalek, P Dell'Oglio, E Zaffuto, O Rodriguez Faba, M Salagierski, J Lingard, M Carini, I Ouzaid, MC Mir, F Montorsi, LF Da Pozzo, C Stief, A Minervini, SD Brookman-May
May 11, 2017
Background
A non-negligible proportion of individuals diagnosed with cT1 renal cell carcinoma (RCC) are upstaged to pT3a at final pathology. Few data on oncological outcomes for these patients are available to determine whether...
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Robert Hawkins, Kate Fife, Michael Hurst, Meng Wang, Niroshini Naicker, Sarah Nolasco, Tim Eisen, Athena Matakidou, Jason Gordon
Oct 02, 2020
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world evidence is limited. Thus, this...
Molecular Targeted Therapy renal cancer Survival Analysis Adolescent Adult Aged Antineoplastic Agents Axitinib Carcinoma Renal Cell Everolimus Female Follow-Up Studies Humans Indazoles Kaplan-Meier Estimate Kidney Neoplasms Longitudinal Studies Male Middle Aged Molecular Targeted Therapy Practice Patterns Physicians' Prognosis Protein Kinase Inhibitors Pyrimidines Retrospective Studies Sulfonamides Sunitinib Treatment Outcome United Kingdom Young Adult
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.
Christopher G Smith, Tina Moser, Florent Mouliere, Johanna Field-Rayner, Matthew Eldridge, Anja L Riediger, Dineika Chandrananda, Katrin Heider, Jonathan C M Wan, Anne Y Warren, James Morris, Irena Hudecova, Wendy N Cooper, Thomas J Mitchell, Davina Gale, Andrea Ruiz-Valdepenas, Tobias Klatte, Stephan Ursprung, Evis Sala, Antony C P Riddick, Tevita F Aho, James N Armitage, Samantha Perakis, Martin Pichler, Maximilian Seles, Gabriel Wcislo, Sarah J Welsh, Athena Matakidou, Tim Eisen, Charles E Massie, Nitzan Rosenfeld, Ellen Heitzer, Grant D Stewart
Mar 31, 2020
BACKGROUND:Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. METHODS:Here, a combination of untargeted and targeted sequencing...
Published by: Genome medicine